LIANY — LianBio Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Brief: Lianbio Announces First Patient Treated In Phase 1 Trial Of Shp2 Inhibitor Bbp-398
Brief: Lianbio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval Of Xdemvy
Brief: LianBio Partner NANOBIOTIX Enters Into License Agreement With Janssen
LianBio rises on clinical supply deal with AstraZeneca
Brief: LianBio Announces Clinical Supply Agreement With Astrazeneca In China
Brief: Lianbio Announces Marketing Approval Of Camzyos® (Mavacamten) In Singapore
U.S. STOCKS ON THE MOVE-Constellation Energy, Cactus, Cardinal Health
U.S. STOCKS ON THE MOVE-CureVac, Aclarion, Baosheng Media
LianBio up on completing enrollment in eye disease drug trial
Brief: LianBio Completes Enrollment In Phase 3 Trial Of TP-03
Brief: LianBio Announces Positive Topline Results From Phase 2A Trial Evaluating Infigratinib In Chinese Patients
LianBio up as cancer drug succeeds in mid-stage trial
Brief: Lianbio Reports First Quarter 2023 Financial Results And Provides Corporate Update
Brief: Lianbio Announces Marketing Approval Of Camzyos In The Macau Special Administrative Region (Sar) Of China
U.S. STOCKS ON THE MOVE-LianBio, Fisker, Roku, Chipotle Mexican
LianBio soars on successful heart disease drug trial in China
Brief: LianBio Announces Positive Topline Results From Phase 3 EXPLORER-CN Trial
Brief: Lianbio Announces China National Medical Products Administration (NMPA) Acceptance With Priority Review Of New Drug Application For Mavacamten For The Treatment Of Patients With Obstructive Hypertrophic Cardiomyopathy
Brief: LianBio Reports Q4 Loss Per Share Of $0.17